Takeda Terminates DNL593 Collaboration with Denali
Analysis based on 8 articles · First reported Apr 03, 2026 · Last updated Apr 03, 2026
The termination of the collaboration between Takeda Pharmaceutical Company and Denali Therapeutics for DNL593 is a mixed signal for the biotechnology market. While Denali Therapeutics regains full control, potentially increasing its upside, it also assumes full development costs and risks, which could impact its stock. The market will closely watch the upcoming Phase 1/2 results for DNL593.
Takeda Pharmaceutical Company has terminated its collaboration agreement with Denali Therapeutics for the co-development and co-commercialization of DNL593, an investigational therapy for frontotemporal dementia-granulin (FTD-GRN). Takeda's decision was based on strategic considerations and not related to the efficacy or safety data of DNL593. As a result, Denali Therapeutics has regained full control and intellectual property rights for DNL593. Denali plans to continue the clinical development of DNL593 independently, utilizing its proprietary Transport Vehicle platform to deliver progranulin to the brain. The company expects to report results from the ongoing Phase 1/2 study in patients with FTD-GRN by the end of 2026. Ryan Watts, CEO of Denali Therapeutics, expressed confidence in the scientific rationale and data generated for DNL593.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard